Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 2/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086758 | 0.83 | IDO1 (0.44) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL20019660 | 0.83 | IDO1 (0.38) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL12676829 | 0.81 | IDO1 (0.37) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL1926906 | 0.79 | IDO1 (0.42) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL28249390 | 0.77 | HDAC3 (0.38) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL874457 | 0.76 | KDM4E (0.48) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL10715442 | 0.75 | IDO1 (0.42) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL980114 | 0.75 | — | — | |
| SCHEMBL30390174 | 0.74 | — | — | |
| SCHEMBL309452 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023709-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2019-01-24 | — | — | US | disclosed |
| US-10100056-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-10-16 | — | — | US | disclosed |
| CN-106459002-B | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2018-08-21 | — | — | CN | disclosed |
| US-20170253596-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | TARO PHARMACEUTICALS INC. (CA) | 2017-09-07 | — | — | US | disclosed |
| CN-106795147-A | Cyclopropyl fused thiazine-2-amine compounds as beta-secretase inhibitors and methods of use | 美国安进公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9434721-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-09-06 | — | — | US | disclosed |
| CN-105753858-A | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA制药株式会社 | 2016-07-13 | — | — | CN | disclosed |
| US-20160083387-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-03-24 | — | — | US | disclosed |
| EP-2970100-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014143561-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| CN-1306935-C | Vasopressin antagonist and oxytocin antagonist | OTASUKA PHARMACEUTICAL CO LTD (JP) | 2007-03-28 | — | — | CN | disclosed |
| US-6156895-A | Process for preparing 4-tert-butyloxycarbonyl-(S)-piperazine-2-tert-butylcarboxamide | MERCK & CO., INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6043387-A | USEFUL AS KEY COMPONENTS IN CATALYSTS FOR ASYMMETRIC REACTIONS, PROVIDING DESIRABLY HIGH ENANTIOMERIC EXCESS | MERCK & CO., INC. (US) | 2000-03-28 | — | — | US | disclosed |
| CN-1039999-C | Vasopressin antagonist and oxytocin antagonist, process for their preparation and pharmaceutical compositions containing them | OTSUKA CHEMICAL CO LTD (JP) | 1998-09-30 | — | — | CN | disclosed |
| CN-1183277-A | Vasopressin antagonist and oxytocin antagonist | OTASUKA PHARMACEUTICAL CO LTD (JP) | 1998-06-03 | — | — | CN | disclosed |
| US-5753644-A | Vasopressin antagonist and oxytocin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5663341-A | RACEMIZATION OF OPTICALLY PURE OR ENRICHED PIPERAZINE-2-TERT-BUTYLCARBOXAMIDE | MERCK & CO., INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5622947-A | VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| CN-1098716-A | Vasopressin antagonists and oxytocin antagonists | OTSUKA CHEMICAL CO LTD (JP) | 1995-02-15 | — | — | CN | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023709-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | HDAC3 1348/4885HDAC1 360/4885HDAC2 1176/4885 |
| US-20160083387-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | HDAC3 1348/4885HDAC1 360/4885HDAC2 1176/4885 |
| US-20170253596-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | HDAC3 1348/4885HDAC1 360/4885HDAC2 1176/4885 |
| US-10100056-B2 | SHIP1 modulators and methods related thereto | PPM1D, PPP1R1B, PPM1A | HDAC3 1348/4885HDAC1 360/4885HDAC2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.